Search clinical trials for: AZD

Total 1389 results

University of Cologne
AstraZeneca

Not yet recruiting

Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) (GUIDANCE)

Small Cell Lung Carcinoma
AstraZeneca
Daiichi Sankyo

Not yet recruiting

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung15)

Metastatic Non-small Cell Lung Cancer
AstraZeneca
Parexel

Recruiting

Drug-Drug Interaction and Safety of AZD4041 Study (Part 1) and Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AZD4041 Study in Opioid Use Disorder (Part 2).

Opioid Use Disorder

United States
AstraZeneca

Recruiting

Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone

Hepatic Impairment

United States
AstraZeneca
Parexel

Recruiting

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral AZD0233 Compared With Placebo in Healthy Adult Participants.

Dilated Cardiomyopathy

United States
AstraZeneca

Not yet recruiting

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer (EvoPAR-BR01)

Advanced Breast Cancer

Canada
Presage Biosciences
AstraZeneca

Recruiting

PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, and Sabestomig in HNSCC

Head and Neck Squamous Cell Carcinoma

United States
AstraZeneca

Recruiting

A Study to Investigate the Safety and Pharmacokinetics of AZD6793 in Healthy Japanese and Chinese Participants

Healthy Participants

United States
AstraZeneca
Daiichi Sankyo

Recruiting

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (TROPION-Lung10)

Non-Small Cell Lung Cancer

Spain, Italy, Japan, Brazil, Taiwan, Korea, Republic of, Australia, Austria, Canada, Poland, United States, Belgium, United Kingdom, Turkey, Hungary, Germany, India
AstraZeneca
Daiichi Sankyo

Not yet recruiting

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer (TROPION-Lung14)

Non-small Cell Lung Cancer

China, Taiwan, Korea, Republic of, Australia
AstraZeneca

Recruiting

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Gastric Cancer | Gastroesophageal Junction Cancer

Canada, Spain, United Kingdom, China, France, Italy, Vietnam, Germany, United States, India, Taiwan, Thailand, Hong Kong, Japan, Switzerland, Poland
AstraZeneca

Recruiting

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 In Healthy Participants

Healthy Participants Study

United States
AstraZeneca

Not yet recruiting

A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure (LUMINARA)

Chronic Heart Failure
Dizal Pharmaceuticals

Recruiting

A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)

Non-small Cell Lung Cancer

China
AstraZeneca

Recruiting

Study of AZD0754 in Participants With Metastatic Prostate Cancer (APOLLO)

Metastatic Prostate Cancer

United States, Australia
AstraZeneca
Parexel

Recruiting

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia

Cardiovascular

United States
AstraZeneca

Recruiting

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

Gastric Cancer | Pancreatic Adenocarcinoma | Gastroesophageal Junction Cancer

United States, Spain, United Kingdom, Korea, Republic of, Japan, Taiwan, Malaysia, Canada, Singapore, Moldova, Republic of, Australia, Georgia
AstraZeneca
Parexel

Not yet recruiting

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia

Cardiovascular

United States
AstraZeneca

Not yet recruiting

LTFU for All Cell and Gene Therapy Studies (LOCUS)

Hepatocellular Carcinoma | Prostate Cancer

United States
AstraZeneca

Recruiting

To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations (NEOLA)

Lung Cancer

Spain, Vietnam, China, India, Taiwan, Thailand, Israel, Turkey, United States, Korea, Republic of
AstraZeneca

Recruiting

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors (CYCAD-1)

ER+ HER2- Advanced Breast Cancer | High-grade Serous Ovarian Cancer (HGSOC)

United Kingdom, Korea, Republic of, Australia, United States, Spain
AstraZeneca

Recruiting

Study of AZD9829 in CD123+ Hematological Malignancies

Hematological Malignancies

United States, Spain, Korea, Republic of, Italy, China, Japan, Taiwan, Australia, Germany
AstraZeneca
AstraZeneca K.K.

Recruiting

A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia (PURSUIT)

Dyslipidemia

Denmark, Hungary, Spain, United States, Japan, Czechia, Slovakia, Canada
AstraZeneca

Recruiting

A Trial to Learn How Safe AZD9550 is in People With Type 2 Diabetes Who Are Overweight or Obese (CONTEMPO)

Non-alcoholic Steatohepatitis (NASH)

Austria, Germany, Japan, Sweden
AstraZeneca

Recruiting

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

B-cell Acute Lymphoblastic Leukemia (B-ALL)

Spain, Canada, Korea, Republic of, United Kingdom, Italy, Germany, Australia, China, Taiwan, United States, France
AstraZeneca

Recruiting

A Single and Multiple Ascending Dose Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD2389 in Healthy Participants

Healthy Participants

United States
AstraZeneca

Recruiting

AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies. (PRIMAVERA)

Lymphoma | Hodgkin Lymphoma | Non-Hodgkin

Australia, Korea, Republic of, United Kingdom, Italy, Germany, France, United States, Spain
AstraZeneca
Parexel

Recruiting

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or Obese

Healthy Participants

United States, United Kingdom, Germany
AstraZeneca

Recruiting

A Study of AZD3470, a PRMT5 Inhibitor, in Patients With MTAP Deficient Advanced/Metastatic Solid Tumours (PRIMROSE)

Advanced Solid Tumours That Are MTAP Deficient

United States, Spain, Korea, Republic of, Australia, Japan, China, Netherlands, France
AstraZeneca
Parexel

Recruiting

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses Via Oral Administration to Healthy Participants

Healthy Participants

United States
AstraZeneca

Recruiting

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents (EvoPAR-PR01)

Metastatic Castration-Sensitive Prostate Cancer

United States, Canada, Spain, United Kingdom, Italy, Australia, Korea, Republic of, Belgium, Germany, Japan, Peru, France, China, India, Taiwan, Thailand, Austria, Brazil, Turkey, Malaysia, Finland, Netherlands, Chile, Hungary, Poland, Sw...
AstraZeneca

Recruiting

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of Subcutaneous AZD6912 in Healthy Participants

Rheumatoid Arthritis

United Kingdom, Canada
AstraZeneca

Recruiting

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States, Spain, Australia, Canada, Germany, China, Japan
AstraZeneca
Parexel

Recruiting

A Placebo-controlled Safety and Tolerability Study of Intravenous (IV) and Subcutaneous (SC) AZD1163 in Healthy Volunteers

Healthy Volunteers

United States, Germany
AstraZeneca

Recruiting

A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma (ATHENA)

Hepatocellular Carcinoma

United States, Korea, Republic of
Takeda
Takeda Development Center Americas, Inc.

Not yet recruiting

A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases

Primary Immunodeficiency Diseases (PID)
AstraZeneca

Recruiting

Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease

Crohn's Disease

Sweden
AstraZeneca

Recruiting

Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA (AJAX)

Asthma

Denmark, United States, South Africa, United Kingdom, Argentina, Vietnam, Brazil, Malaysia, Taiwan, France, Germany, Spain, Thailand, Bulgaria, Philippines, Sweden
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) With Osimertinib for the Treatment of Patients With Oligoprogressive EGFR Positive Non-small Cell Lung Carcinoma

Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8

United States
AstraZeneca

Recruiting

Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

Gastric Cancer | Pancreatic Ductal Adenocarcinoma | Esophageal Adenocarcinoma | Gastro-esophageal Junction Cancer

Korea, Republic of, United States, Japan, Taiwan, China, United Kingdom, Netherlands
Montefiore Medical Center
M.D. Anderson Cancer Center; Flamingo Therapeutics NV

Recruiting

Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML

Acute Myeloid Leukemia | Myelodysplastic Syndromes | AML/MDS

United States
Peking University
AstraZeneca

Recruiting

Phase 1 Trial of AZD6422 in CLDN18.2+ GI Tumors

Gastrointestinal Tumors

China
Henan Cancer Hospital

Recruiting

Go-CHOP as the Frontline Therapy for PTCL

Peripheral T Cell Lymphoma

China
AstraZeneca
Austrian Breast and Colorectal Cancer Study Group (ABCSG)

Recruiting

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) (CAMBRIA-2)

Breast Cancer, Early Breast Cancer

United States, Spain, Italy, Korea, Republic of, Belgium, Canada, Poland, Portugal, United Kingdom, France, China, Germany, Japan, Mexico, Thailand, Hungary, Australia, Austria, Brazil, Colombia, Taiwan, Malaysia, Philippines, Romania, ... and more
AstraZeneca

Recruiting

A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer. (ASCERTAIN)

Prostate Cancer

United States, Spain, United Kingdom, Netherlands, Canada, Australia
AstraZeneca

Recruiting

A Phase I Study to Investigate the Effect of Hepatic Impairment on the PK, Safety, and Tolerability of AZD2693

Hepatic Impairment

United States
The First Affiliated Hospital of Guangzhou Medical...
Guangdong Provincial Hospital of Traditional Chinese Medicine; Tongji Hospital and other collaborators

Not yet recruiting

Biomarkers for Predicting the Response to Inhaled Corticosteroid in Patients With Chronic Cough. (CC-ICS)

Cough

China
Flamingo Therapeutics NV

Recruiting

Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC (PEMDA-HN)

HNSCC

United States, Korea, Republic of
First Affiliated Hospital Xi'an Jiaotong University

Not yet recruiting

Study on the Efficacy and Safety of MA-BUCY2 Conditioning in High-risk AML Patients Underwent Haplo-HSCT

Conditioning | Haploidentical Stem Cell Transplantation

China
AstraZeneca
AstraZeneca K.K.

Recruiting

A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis (FORTUNA)

Nonalcoholic Steatohepatitis

United States, China, Korea, Republic of, Germany, Japan, Spain, Vietnam, Argentina, Colombia, Peru, Brazil, Malaysia, Taiwan, Thailand, Italy, Turkey, Hong Kong, Singapore, India, Mexico, Chile, Philippines, Portugal

3

Subscribe